He needs to explain the status of HemoDefend. I am very disappointed he is blowing this off completely. Chan went from a partner by EOY 2013 to nothing in Sept 2014. Also....five new products this year?? He needs to tell us if HemoDefend is on the back burner....if so...then we know the five new products may be as well. Integrity, transparency and credibility are character traits I look for in a CEO and management....he is pushing me to the limits on all three.
Most BO's come at a premium of lower than 2x the pps. If you want to see 2.50, Punit needs to get the pps organically and materially valued over a dollar before the vultures come flying in. Many times, the vultures are the MM's that put a lid on the pps.
If NDA for Etep is pushed to 2015 then I'll concede to disappointment. However, Chris still has more than 3 months.
Perhaps this is one of the reasons why the CSO is gone......disagreement on this strategy....just speculating
If this all happens without effecting the time line for NDA submission, then it is the right thing to do. Chris wants to get the biggest bang out of these trials. By including a broader scope of exons, it will increase the market and solidify and validate the exon skipping platform for both safety and efficacy. Six more weeks, for a much broader and stronger trial, without pushing the Etep NDA back.
Gary has a poster that has stolen his ID (i vs 1). Gary, you must feel proud to have someone want to be you. As for the imposter, you have no self esteem....do you?
Sorry, lost the other paragraph. However, to paraphrase, 4 prominent and reputable institutions are using the filters as SOC for certain conditions. Hopefully that will continue to spread...i.e. new utilization with new institutions and conditions and repeat orders due to expanding and ongoing SOC's.
Enormous potential in combating sepsis" therefore sees the senior physician in the Department of Intensive Care Medicine at the University Hospital Hamburg Eppendorf, Axel Nierhaus. Professor Karl carrier, director of the cardiac intensive care unit of Universtätsklinikums Ulm, who proved to be one of the first heart specialists, the reduction of inflammatory mediators through the adsorber, notes, Cytosorb was a "promising new treatment option" and have "greatest benefit".
What is exactly is still difficult to discern. As the Eppendorf intensivists Nierhaus recently got a suicidal patients on his ward, who had swallowed an overdose of the painkiller acetaminophen, it was no longer pump the stomach. The active ingredients of the drug had already paralyzed the liver. Nierhaus put the cytokine filter - and rescued the man and life liver. Less
Most of my bio techs are down...not SRPT specific, but still no fun to watch. The Pharma and Bio tech indexes (ETF's) are sharply down.
Biotechnology companies shares down at 10 a.m.
2 hours ago
Final Glance: Biotechnology companies Associated Press
Early Glance: Education companies Associated Press
Early Glance: Managed Care companies Associated Press
Early Glance: Computer companies Associated Press
Early Glance: Tools and Appliances companies Associated Press
NEW YORK (AP) -- Shares of some top biotechnology companies are down at 10 a.m.:
Amgen Inc. fell $.84 or .6 percent, to $137.05.
Biogen Idec fell $5.40 or 1.7 percent, to $317.99.
Celgene Corp. fell $2.34 or 2.6 percent, to $89.18.
Gilead Sciences Inc. fell $2.86 or 2.8 percent, to $100.80.
Meeting with the FDA this week or next....if on schedule. This will give more clarity to the NDA timeline and probability for success.
Agreed. There have been a lot of catalysts that have been projected for this year, Chan is behind on delivering....HemoDefend, partnerships, new products, interim data, FDA trial design etc.......However, the only projection I hope he is late on (at least at this juncture), is the R/S up list.
I hope we can accompliishing garnering institutional investors through organic growth. However...per below discussion:
The problem is when you are conceding to a buffer, you are essentially embracing a post sell off R/S. You go to 2 or 5 (what ever) and want to hold 1 or 3 without substantive maintenance/growth data/partnership amo to prohibit the post R/S sell off. This happens a lot in up listing. I usually always keep dry powder for a subsequent ell off post R/s Up list. The street knows when you are over extending your up list only to be able to maintain it for 30 consecutive days (example). Punit needs to be smart and about his pps targets. Targets that will bring in institutional investors, not traders, which is what the R/S...up list is strategically designed to do
Thanks for the heads up. If you are successful, I will buy the new bottom. Your help in accumulating at bargain prices is appreciated....the prize is 6 to 9 months out. Have a great weekend.
AMRN???? What are you smoking? I have no clue what you are talking about. This is the RNN board.....Hello
I know Jet. He's the real deal and his intent is always genuine and sincere. He is also very qualified. He would be the first to admit these bio techs are risky, but he does his DD. He is the investment founder of ISIS. BTW, Jet, been in the river slamin salmon?
Thumbs up post. IMSC also traveled with our Government recently. Why would they create an alliance with a company they do not see value in. American made, high risk environment, Government supported, easy, safe and effective technology, motivated and competent management team, product needed around the ENTIRE world for a massive market, commercial and government market, credentialed and much more to come. I am still a buyer below 2. GLTA
You must be a multi-millionaire to put that much money into this lottery. I wish you well. I am down to a measly 140,000 shares. After 6 years and 6 different technologies/platforms they have basically NO revenue, billions of diluted OS and essentially two employees. No, I am not adding. I always wish any investor well. I hate bashers and jealous sideliners when something finally comes to fruition...so I am sincere when I say I hope this hits 5 plus dollars some day. How long have you been in this stock? Just curious.